FY2025 EPS Forecast for Pharma-Bio Serv Lowered by Analyst

Pharma-Bio Serv Inc. (OTCMKTS:PBSV) – Research analysts at Zacks Small Cap decreased their FY2025 earnings per share estimates for shares of Pharma-Bio Serv in a note issued to investors on Tuesday, September 16th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of $0.02 for the year, down from their prior estimate of $0.06. The consensus estimate for Pharma-Bio Serv’s current full-year earnings is $0.11 per share.

Pharma-Bio Serv (OTCMKTS:PBSV) last issued its quarterly earnings results on Monday, September 15th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.04). The business had revenue of $1.96 million for the quarter, compared to the consensus estimate of $3.00 million. Pharma-Bio Serv had a negative net margin of 0.91% and a negative return on equity of 0.68%.

Pharma-Bio Serv Stock Performance

Shares of OTCMKTS PBSV opened at $0.57 on Wednesday. The stock has a market cap of $13.07 million, a price-to-earnings ratio of -57.00 and a beta of 0.64. Pharma-Bio Serv has a 1-year low of $0.31 and a 1-year high of $0.67. The stock’s 50-day moving average is $0.60 and its 200 day moving average is $0.53.

About Pharma-Bio Serv

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies.